Journal
ONCOTARGETS AND THERAPY
Volume 11, Issue -, Pages 7005-7009Publisher
DOVE MEDICAL PRESS LTD
DOI: 10.2147/OTT.S170385
Keywords
immune checkpoint; clinical trial; cancer immunotherapy; T-cell immunoglobulin and mucin domain-3 (TIM-3)
Categories
Funding
- National Natural Science Foundation of China [81802255]
- Shanghai Pujiang Program [17PJD036]
- Shanghai Municipal Commission of Health and Family Planning Program [20174Y0131]
- National key research & development project [2016YFC0902300]
- Major disease clinical skills enhancement program of three year action plan for promoting clinical skills and clinical innovation in municipal hospitals
- Shanghai Shen Kang Hospital Development Center Clinical Research Plan of SHDC [16CR1001A]
- fundamental research funds for the central universities
Ask authors/readers for more resources
Patients with malignant tumor treated with immunotherapy have received significant clinical benefits over the years. Immune checkpoint blocking agents, such as anti-cytotoxic T-lymphocyte-associated protein-4 (anti-CTLA-4) and anti-programmed cell death protein-1 (anti-PD-1) monoclonal antibodies, have produced impressive clinical results in different types of cancer. T-cell immunoglobulin and mucin domain-3 (TIM-3), another immune checkpoint, could inhibit cancer immunity. Recent studies have highlighted that TIM-3 has an important role to play in T-cell exhaustion and correlates with the outcome of anti-PD-1 therapy. Targeting TIM-3 might be a promising approach for cancer immunotherapy. Here, we review the role of TIM-3 in cancer and clinical trials with TIM-3 inhibitors.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available